Acadia Pharmaceuticals
ACAD
199 hedge funds and large institutions have $3.7B invested in Acadia Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 71 increasing their positions, 60 reducing their positions, and 23 closing their positions.
64% more capital invested
Capital invested by funds: $2.26B → $3.7B (+$1.45B)
57% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 23
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
19% more call options, than puts
Call options by funds: $33M | Put options by funds: $27.8M
18% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 60
7% more funds holding
Funds holding: 186 → 199 (+13)
1.31% less ownership
Funds ownership: 97.22% → 95.91% (-1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$30.9M |
| 2 |
D.E. Shaw & Co
New York
|
+$30.1M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$20.5M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$18.1M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$16.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$50.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$43.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$24.8M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$17.6M |
| 5 |
Citigroup
New York
|
-$15.6M |
ACAD Hedge Fund Activity: Q1 2019 in Review
199 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q1 2019, worth a combined $3.7B — up 64% from $2.26B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ACAD positions and 23 closed out — a net gain of 13 holders — while 71 added to existing stakes and 60 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $30.9M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $50.8M sold.
- 199 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q1 2019, up from 186 in Q4 2018.
- Funds reported $3.7B of Acadia Pharmaceuticals stock for Q1 2019, up 64% quarter-over-quarter.
- 36 funds opened new Acadia Pharmaceuticals positions in Q1 2019 and 23 closed out, a net change of +13 holders.
- The largest Acadia Pharmaceuticals buyer in Q1 2019 was Avoro Capital Advisors, an estimated $30.9M added.
- The largest Acadia Pharmaceuticals seller in Q1 2019 was Janus Henderson Group, an estimated $50.8M sold.
Based on aggregated 13F filings for Q1 2019.